GlassScriptPhysician profile
Sejan B Patel
NPI 1417149717
$3,905.98
in general payments reported to CMS, 2019-2025
25 companies · $681 in 2025
The $681 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $52.39 · 2021: $200 · 2022: $385 · 2023: $1,928 · 2024: $416 · 2025: $681.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956 · Travel and Lodging: $1,054 · Education: $15.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,955.75 |
| Travel and Lodging | $1,054.45 |
| Education | $15.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $1,675.64 | 2019-2025 | Covera, Fluency Endovascular Stent Graft, Venovo |
| Otsuka America Pharmaceutical, INC. | $436.43 | 2019-2025 | Jynarque |
| Amgen INC. | $397.11 | 2022-2025 | Krystexxa, Tavneos, Aranesp |
| W. L. Gore & Associates, INC. | $358.20 | 2019-2025 | Gore Viabahn Endoprosthesis, Gore Viabahn Endoprosthesis With Heparin, Viabahn Endoprosthesis With Propaten Bioactive Surface |
| Fresenius USA Marketing, INC. | $292.58 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Nxstage Medical, INC. | $79.76 | 2022-2023 | Nxstage System One |
| Ardelyx, INC. | $66.17 | 2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $65.21 | 2020-2023 | Farxiga |
| Horizon Therapeutics Plc | $58.49 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $54.60 | 2022-2024 | Benlysta, Jesduvroq |
| Aurinia Pharma U.S., INC. | $44.32 | 2023 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $42.59 | 2022-2023 | Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.33 | 2023-2024 | Jardiance |
| Akebia Therapeutics INC | $38.02 | 2019-2020 | |
| Venturemed Group, INC. | $36.55 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $36.16 | 2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $35.59 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $28.91 | 2019-2021 | |
| Vifor Pharma, INC. | $26.51 | 2023 | Veltassa |
| Ani Pharmaceuticals, INC. | $23.86 | 2024 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $21.24 | 2023 | Acthar |
| Genzyme Corporation | $20.15 | 2019 | |
| Redhill Biopharma INC. | $14.15 | 2022 | |
| Av Medical Technologies LTD. | $9.75 | 2019 | |
| Travere Therapeutics, INC. | $1.66 | 2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sejan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.